Chai Discovery Secures $70 Million in Series A Funding
Chai Discovery, an AI company based in San Francisco, has successfully raised $70 million in Series A financing. The funding round was led by Menlo Ventures, with participation from other investors such as Yosemite, DST Global Partners, SV Angel, and more. Mikael Dolsten M.D., PhD., former Pfizer Chief Scientific Officer, will be joining the company’s board of directors.
Accelerating Life-Changing Therapeutics
Founded in 2024 by industry veterans, Chai Discovery specializes in predicting and reprogramming the interactions between biochemical molecules. Their innovative AI platform, Chai, has already made significant strides in the field of drug discovery. The company plans to use the latest funding to further develop their platform and collaborate with strategic partners to target previously inaccessible molecules.
Recent Breakthroughs and Future Goals
Chai Discovery recently launched Chai-2, a breakthrough in antibody design that boasts an impressive near-20% hit rate. This new technology allows for the generation of successful binders from scratch against a wide range of targets. With a track record of success and a team of experienced researchers and engineers, Chai Discovery is well-positioned to continue driving innovation in the field of AI-driven therapeutics.
